# Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC

> **NCT00322335** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 230 (actual)

## Conditions studied

- Haemophilus Influenzae Type b
- Neisseria Meningitidis

## Interventions

- **BIOLOGICAL:** Haemophilus influenzae type b- and meningococcal (vaccine)
- **BIOLOGICAL:** Infanrix™ penta
- **BIOLOGICAL:** Infanrix™ hexa
- **BIOLOGICAL:** Engerix-B
- **BIOLOGICAL:** NeisVac-C™
- **BIOLOGICAL:** Infanrix™ IPV/HIB
- **BIOLOGICAL:** Meningitec™

## Key facts

- **NCT ID:** NCT00322335
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2006-07
- **Final completion:** 2010-09
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2016-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322335, "Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00322335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*